U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H14FN3O3
Molecular Weight 303.2889
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUMAZENIL

SMILES

CCOC(=O)c1c2CN(C)C(=O)c3cc(ccc3-n2cn1)F

InChI

InChIKey=OFBIFZUFASYYRE-UHFFFAOYSA-N
InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/cdi/flumazenil.html

Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. Fumazenil is used for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures. Flumazenil went off patent in 2008 so at present generic formulations of this drug are available.

CNS Activity

Originator

Approval Year

1991
52
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
1131
Antagonist
1131
 3.3 nM [Ki]
Antagonist
1131
 148.0 nM [Ki]
Gamma-aminobutyric acid receptor subunit gamma-2
2
Target ID: P18507
Gene ID: 2566.0
Gene Symbol: GABRG2
Target Organism: Homo sapiens (Human)
Antagonist
1131
Antagonist
1131
 8.1 nM [Ki]
Antagonist
1131
 5.7 nM [Ki]
Antagonist
1131
 2.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
4033
FLUMAZENIL

Approved Use

Flumazenil Injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose.

Launch Date

1.09745281E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.98 ng/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
45.9 ng/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
0.2 mg single, intravenous
dose: 0.2 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.28 ng/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12 ng × h/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.9 ng × h/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
0.2 mg single, intravenous
dose: 0.2 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.1 ng × h/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.05 h
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.18 h
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
0.2 mg single, intravenous
dose: 0.2 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.12 h
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
Doses

Doses

DosePopulationAdverse events​
3 mg single, intravenous
Highest studied dose
Dose: 3 mg
Route: intravenous
Route: single
Dose: 3 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/1647443/
unhealthy, 32-62
n = 10
Health Status: unhealthy
Condition: epilepsy
Age Group: 32-62
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/1647443/
Sources:
https://pubmed.ncbi.nlm.nih.gov/1647443/
7.13 mg single, intravenous (mean)
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
n = 87
Health Status: unhealthy
Condition: benzodiazepine overdose
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Population Size: 87
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Other AEs: Injection site pain, Agitation...
Other AEs:
Injection site pain (10.3%)
Agitation (8%)
Anxiety (3.4%)
Crying abnormal (3.4%)
Headache (3.4%)
Vomiting (3.4%)
Tachycardia (3.4%)
Dizziness (3.4%)
Nausea (2.3%)
Convulsions (1.1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/9695999/
unhealthy, adult
n = 265
Health Status: unhealthy
Condition: hepatic encephalopathy
Age Group: adult
Sex: M+F
Population Size: 265
Sources:
https://pubmed.ncbi.nlm.nih.gov/9695999/
Sources:
https://pubmed.ncbi.nlm.nih.gov/9695999/
AEs

AEs

AESignificanceDosePopulation
Convulsions 1.1%
7.13 mg single, intravenous (mean)
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
n = 87
Health Status: unhealthy
Condition: benzodiazepine overdose
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Population Size: 87
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Injection site pain 10.3%
7.13 mg single, intravenous (mean)
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
n = 87
Health Status: unhealthy
Condition: benzodiazepine overdose
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Population Size: 87
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Nausea 2.3%
7.13 mg single, intravenous (mean)
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
n = 87
Health Status: unhealthy
Condition: benzodiazepine overdose
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Population Size: 87
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Anxiety 3.4%
7.13 mg single, intravenous (mean)
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
n = 87
Health Status: unhealthy
Condition: benzodiazepine overdose
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Population Size: 87
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Crying abnormal 3.4%
7.13 mg single, intravenous (mean)
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
n = 87
Health Status: unhealthy
Condition: benzodiazepine overdose
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Population Size: 87
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Dizziness 3.4%
7.13 mg single, intravenous (mean)
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
n = 87
Health Status: unhealthy
Condition: benzodiazepine overdose
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Population Size: 87
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Headache 3.4%
7.13 mg single, intravenous (mean)
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
n = 87
Health Status: unhealthy
Condition: benzodiazepine overdose
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Population Size: 87
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Tachycardia 3.4%
7.13 mg single, intravenous (mean)
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
n = 87
Health Status: unhealthy
Condition: benzodiazepine overdose
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Population Size: 87
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Vomiting 3.4%
7.13 mg single, intravenous (mean)
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
n = 87
Health Status: unhealthy
Condition: benzodiazepine overdose
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Population Size: 87
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Agitation 8%
7.13 mg single, intravenous (mean)
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
n = 87
Health Status: unhealthy
Condition: benzodiazepine overdose
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Population Size: 87
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
activator
39

inducer
374

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CES1
13

P-gp
724
CYP2B6
243

CYP1A2
329
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
805
 no
CYP1A2
805
 no
CYP2B6
465
 no
CYP2B6
465
 no
CYP3A4
920
 no
CYP3A4
920
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CES1
13
 yes
P-gp
724
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5103
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5103
ChemicalBook
CB9208108
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9208108
MolPort
MolPort-003-666-855
https://www.molport.com/shop/molecule-link/MolPort-003-666-855
Selleck Chemicals
Flumazenil
http://www.selleckchem.com/products/Flumazenil.html
ZINC
ZINC000000001464
http://zinc15.docking.org/substances/ZINC000000001464
eMolecules
538442
https://www.emolecules.com/cgi-bin/more?vid=538442
PubMed

PubMed

TitleDatePubMed
A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users.
1999 Nov
Flumazenil challenge in social phobia.
2000
[Delayed postanoxic encephalopathy].
2000 Aug
Voluntary self-poisoning as a cause of admission to a tertiary hospital internal medicine clinic in Piraeus, Greece within a year.
2001
Flumazenil use in an emergency department: a survey.
2001
Different sensitivities to competitive inhibition of benzodiazepine receptor binding of 11C-iomazenil and 11C-flumazenil in rhesus monkey brain.
2001 Apr
Effects of diazepam and flumazenil on minimum alveolar concentrations for dogs anesthetized with isoflurane or a combination of isoflurane and fentanyl.
2001 Apr
Neocortical abnormalities of [11C]-flumazenil PET in mesial temporal lobe epilepsy.
2001 Apr 10
Diazepam increases the hypothalamic-pituitary-adrenocortical (HPA) axis activity by a cyclic AMP-dependent mechanism.
2001 Aug
The effects of benzodiazepines on human opioid receptor binding and function.
2001 Aug
Delayed synaptic dysfunction of association cortices in carbon monoxide intoxication.
2001 Dec
Brain function in social anxiety disorder.
2001 Dec
Involvement of benzodiazepine binding sites in an antiaggressive effect by 5-HT(1A) receptor activation in isolated mice.
2001 Dec 7
Asymmetrical localization of benzodiazepine receptors in the human auditory cortex.
2001 Jan
A small dose of midazolam decreases the time to achieve hypnosis without delaying emergence during short-term propofol anesthesia.
2001 Jun
Mice performance on the staircase test following acute ethanol administration.
2001 Mar
Behavioral and pharmaco-toxicological study of Papaver rhoeas L. in mice.
2001 Mar 3
Modification of the effects of benzodiazepines on the exploratory behaviors of mice on a hole-board by diabetes.
2001 May
Flumazenil's reversal of myoclonic-like movements associated with midazolam in term newborns.
2001 May
Absolute quantification by positron emission tomography of the endogenous ligand.
2001 May
Loss of the major GABA(A) receptor subtype in the brain is not lethal in mice.
2001 May 15
Behavioral effects of agents active at the gamma-aminobutyric acid receptor complex in the staircase paradigm.
2001 May 18
Neuroreceptor bindings and synaptic activity in visual system of monocularly enucleated rat.
2001 May-Jun
Estimation of regional cerebral blood flow levels in ischemia using [(15)O]water of [(11)C]flumazenil PET without arterial input function .
2001 May-Jun
The negative GABA(A) modulator methyl beta-carboline-3-carboxylate attenuates the behavioral effects of the positive GABA(A) modulators triazolam and pregnanolone in rhesus monkeys.
2001 Nov
Flumazenil improves cognitive and neuromotor emergence and attenuates shivering after halothane-, enflurane- and isoflurane-based anesthesia.
2001 Nov
Confluence of antianalgesic action of diverse agents through brain interleukin(1beta) in mice.
2001 Nov
[Functional imaging (PET and SPECT) in epilepsy].
2001 Nov 4
Benzodiazepines in the intensive care unit.
2001 Oct
Biodistribution, binding specificity and metabolism of [18F]fluoroethylflumazenil in rodents.
2001 Oct
Potency of positive gamma-aminobutyric acid(A) modulators to substitute for a midazolam discriminative stimulus in untreated monkeys does not predict potency to attenuate a flumazenil discriminative stimulus in diazepam-treated monkeys.
2001 Sep
Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic.
2002 Jan 2
Patents

Patents

04346030
6
04346036
6
04352818
7
JP2008201796A
1

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Reversal of Sedation Initial dose: 0.2 mg IV one time over 15 seconds. Repeated doses: 0.2 mg may be given every minute until the desired level of consciousness is achieved. Maximum total dose 1 mg. Most patients respond to 0.6 to 1 mg.
Route of Administration: Intravenous
In Vitro Use Guide
Exposure (48 h) of human embryonic kidney (HEK) 293 cells stably expressing recombinant alpha1beta2gamma2S GABAA receptors to flumazenil (1 or 5 uM) in the presence of GABA (1 uM) enhanced the maximum number (Bmax) of [3H]flunitrazepam binding sites without affecting their affinity (Kd).
Name Type Language
FLUMAZENIL
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
ANEXATE
Brand Name English
FLUMAZENIL [USAN]
Common Name English
RO-15-1788
Code English
FLUMAZENIL [MI]
Common Name English
FLUMAZEPIL
Common Name English
MAZICON
Brand Name English
FLUMAZENIL [USP-RS]
Common Name English
FLUMAZENIL [VANDF]
Common Name English
ETHYL 8-FLUORO-5,6-DIHYDRO-5-METHYL-6-OXO-4H-IMIDAZO(1,5-A)(1,4)BENZODIAZEPINE-3-CARBOXYLATE
Systematic Name English
RO-151788
Code English
FLUMAZENIL [MART.]
Common Name English
RO-151788000
Code English
NSC-759193
Code English
RO 15-1788/000
Code English
RO-1722
Code English
FLUMAZENIL [EP MONOGRAPH]
Common Name English
FLUMAZENIL [ORANGE BOOK]
Common Name English
LANEXAT
Brand Name English
FLUMAZENIL [USP MONOGRAPH]
Common Name English
ROMAZICON
Brand Name English
4H-IMIDAZO(1,5-A)(1,4)BENZODIAZEPINE-3-CARBOXYLIC ACID, 8-FLUORO-5,6-DIHYDRO-5-METHYL-6-OXO-, ETHYL ESTER
Common Name English
FLUMAZENIL [WHO-DD]
Common Name English
FLUMAZENIL [INN]
Common Name English
RO-15-1788/000
Code English
FLUMAZENIL [JAN]
Common Name English
RO-41-8157
Code English
Classification Tree Code System Code
WHO-ATC V03AB25
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
WHO-VATC QV03AB25
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
NCI_THESAURUS C1012
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
NDF-RT N0000175680
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
Code System Code Type Description
INN
5311
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
RXCUI
4457
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY RxNorm
EVMPD
SUB07693MIG
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
PUBCHEM
3373
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
MERCK INDEX
M5436
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C47534
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
EPA CompTox
78755-81-4
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
IUPHAR
4192
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
DRUG CENTRAL
1195
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
WIKIPEDIA
FLUMAZENIL
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
MESH
D005442
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
ChEMBL
CHEMBL407
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
CAS
78755-81-4
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
USP_CATALOG
1273808
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY USP-RS
DRUG BANK
DB01205
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
FDA UNII
40P7XK9392
Created by admin on Fri Jun 25 21:03:52 UTC 2021 , Edited by admin on Fri Jun 25 21:03:52 UTC 2021
PRIMARY
ACTIVE MOIETY
Structure of FLUMAZENIL
METABOLITE (PARENT)
Structure of N-DESMETHYLFLUMAZENIL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966